| Type 2 Diabetes Mellitus |
1 |
1 |
| COVID-19 |
0 |
0.9 |
| Weight Loss |
0 |
0.67 |
| Remission |
0 |
0.55 |
| Obesity |
0 |
0.52 |
| Weight Management |
0 |
0.47 |
| Type 1 Diabetes Mellitus |
0 |
0.46 |
| Pancreas Transplantation |
0 |
0.21 |
| Islet Cell Transplantation |
0 |
0.2 |
| Pandemic |
0 |
0.18 |
| Transplantation |
0 |
0.18 |
| Cell Transplantation |
0 |
0.17 |
| Social Determinants of Health |
0 |
0.16 |
| Biologic Therapy |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Health Care Inequities |
0 |
0.12 |
| Pancreas |
0 |
0.12 |
| Surgery |
0 |
0.12 |
| Stem Cell Research and Therapy |
0 |
0.11 |
| GLP-1 Receptor Agonist |
0 |
0.1 |
| Deliberate Self-Harm |
0 |
0.09 |
| Immune Tolerance |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Sleep Disorders |
0 |
0.08 |
| Child |
0 |
0.06 |
| Chronic Disease |
0 |
0.06 |
| Colorado |
0 |
0.06 |
| Diabetes Research |
0 |
0.06 |
| Endocrine Society |
0 |
0.06 |
| Epidemiology |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Health Equity |
0 |
0.06 |
| Hyperglycemia |
0 |
0.06 |
| Hypoglycemia |
0 |
0.06 |
| Immunization |
0 |
0.06 |
| Incretin Hormone |
0 |
0.06 |
| Injury |
0 |
0.06 |
| Interleukin-2 |
0 |
0.06 |
| Kidney |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Nightmares |
0 |
0.06 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.06 |
| Racism |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Stigma |
0 |
0.06 |
| Suicide |
0 |
0.06 |
| Tolerance |
0 |
0.06 |
| UK Site Content |
0 |
0.06 |
| Depression |
0 |
0.04 |
| Wound Management |
0 |
0.04 |